Brooks Laboratories Ltd
₹67.11
(-1.31%)
Tue, 03 Mar 2026, 03:55 am
Health Technology
Pharmaceuticals: Major
24.5KBrooks Laboratories Enterprise Value (EV)
| Particulars | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 0 | 0 | 2.99 | 3.68 | 4.12 | 6.54 | 13.08 | 131.41 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Price to book ratio | 0 | 0 | 0 | 0 | 0 | 0.29 | 0.25 | 0.27 | 0.56 | 1.14 | 1.71 | 1.13 | 0.82 | 0.38 | 1.94 | 2.05 | 2.09 | 3.71 | 3.24 |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | 0.47 | 0.33 | 0.35 | 0.73 | 1.74 | 3.81 | 2.32 | 1.61 | 0.39 | 1.99 | 1.98 | 2.46 | 3 | 3.51 |
| Price to cash flow ratio | 0 | 0 | 0 | 0 | 0 | 0 | 4.95 | 2.55 | 15.44 | 16.15 | 25.28 | 0 | 0 | 0 | 95.02 | 0 | 0 | 0 | 154.52 |
| Enterprise value | 0 | 0 | 0 | 0 | 0 | 77.81M | 35.21M | -670780 | 395.01M | 1.43B | 2.31B | 1.56B | 1.16B | 530.53M | 1.83B | 2.48B | 1.6B | 2.43B | 2.95B |
| Enterprise value to EBITDA ratio | 0 | 0 | 0 | 0 | 0 | 0.73 | 0.34 | -0.01 | 5.76 | 12.59 | 45.81 | 0 | 0 | 0 | 0 | 0 | 0 | 81.65 | 61.96 |
| Debt to equity ratio | 4.58 | 2.31 | 1.92 | 0.87 | 0.45 | 0.01 | 0.01 | 0 | 0 | 0.05 | 0.11 | 0.24 | 0.30 | 0.28 | 0.40 | 0.29 | 0.09 | 0.09 | 0.08 |
| Return on equity % | 0 | 100.89 | 43.16 | 47.32 | 41.82 | 15.97 | 7.26 | 6.65 | 8.46 | 9.11 | 1.33 | -11.38 | -13.48 | -23.95 | -21.82 | -13.55 | -25.88 | -28.08 | -12.18 |
Brooks Laboratories Ltd Enterprise Value
The Brooks Laboratories Ltd Enterprise Value is a key financial metric used by investors to evaluate Brooks Laboratories Ltd's valuation, profitability, and overall financial performance. Tracking the Brooks Laboratories Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Brooks Laboratories Ltd (NSE: BROOKS, BSE: 533543) is currently trading at ₹67.11, with a market capitalization of ₹1.99B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Brooks Laboratories Ltd Enterprise Value is essential for fundamental analysis.
Brooks Laboratories Ltd Enterprise Value Current Value
The current Brooks Laboratories Ltd Enterprise Value stands at 2.95B.
The latest Brooks Laboratories Ltd Enterprise Value has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Brooks Laboratories Ltd Enterprise Value Historical Trend
The Brooks Laboratories Ltd Enterprise Value has shown the following historical trend:
- 2024: 2.95B
- 2023: 2.43B
- 2022: 1.6B
- 2021: 2.48B
- 2020: 1.83B
The recent rise in Brooks Laboratories Ltd Enterprise Value suggests strengthening valuation trends and improving market sentiment.
What Brooks Laboratories Ltd Enterprise Value Indicates for Investors
The Brooks Laboratories Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Brooks Laboratories Ltd.
Brooks Laboratories Ltd Enterprise Value Analysis Summary
The Brooks Laboratories Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Brooks Laboratories Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Brooks Laboratories Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800